Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mayo Clinic Laboratories, |
RCV001508790 | SCV001715163 | uncertain significance | not provided | 2020-08-18 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002567998 | SCV003679275 | uncertain significance | Inborn genetic diseases | 2022-02-10 | criteria provided, single submitter | clinical testing | The c.7174G>A (p.E2392K) alteration is located in exon 50 (coding exon 50) of the PIEZO1 gene. This alteration results from a G to A substitution at nucleotide position 7174, causing the glutamic acid (E) at amino acid position 2392 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Revvity Omics, |
RCV001508790 | SCV003812931 | uncertain significance | not provided | 2023-11-07 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003394083 | SCV004119595 | uncertain significance | PIEZO1-related disorder | 2023-06-19 | criteria provided, single submitter | clinical testing | The PIEZO1 c.7174G>A variant is predicted to result in the amino acid substitution p.Glu2392Lys. To our knowledge, this variant has not been reported in individuals with PIEZO1-related disease. This variant is reported in 0.078% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/16-88782483-C-T). In ClinVar, this variant is classified as uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/1163588/). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
OMIM | RCV003152632 | SCV003841036 | affects | Blood group, ER | 2023-01-26 | no assertion criteria provided | literature only | |
OMIM | RCV003152633 | SCV003841038 | pathogenic | ER BLOOD GROUP SYSTEM, ER(a-b-) | 2023-01-26 | no assertion criteria provided | literature only |